Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Down 13.4% in March

Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 748,000 shares, a decrease of 13.4% from the February 28th total of 863,500 shares. Currently, 1.9% of the company's stock are short sold. Based on an average daily volume of 231,500 shares, the short-interest ratio is presently 3.2 days.

Kronos Bio Price Performance

Shares of KRON traded down $0.01 during midday trading on Monday, hitting $0.77. The stock had a trading volume of 33,308 shares, compared to its average volume of 269,002. The firm has a market cap of $46.82 million, a price-to-earnings ratio of -0.54 and a beta of 1.78. The company has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $0.95. Kronos Bio has a twelve month low of $0.69 and a twelve month high of $1.60.

Kronos Bio (NASDAQ:KRON - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.13). Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%. The firm had revenue of $2.27 million during the quarter, compared to analyst estimates of $1.00 million. Analysts forecast that Kronos Bio will post -1.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP bought a new position in shares of Kronos Bio in the 4th quarter valued at about $33,000. GTS Securities LLC bought a new position in Kronos Bio in the fourth quarter valued at approximately $48,000. Squarepoint Ops LLC acquired a new position in shares of Kronos Bio during the 4th quarter worth approximately $93,000. Kennedy Capital Management LLC raised its stake in shares of Kronos Bio by 8.7% during the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company's stock worth $142,000 after purchasing an additional 12,007 shares in the last quarter. Finally, Gilead Sciences Inc. acquired a new stake in shares of Kronos Bio in the 4th quarter valued at approximately $179,000. Institutional investors own 64.09% of the company's stock.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.